Leukemia Clinical Trials

Phase I Agents for Hematologic Malignancies

• GSK525762 (2013-0527) (NCT01943851)
• Hu8F4 (2014-0057) (NCT02530034) 
• Ruxolitinib + DAC (2014-0344) (NCT02257138)
• Bosutinib + Inotuzumab (2014-0435) (NCT02311998)
•  APTO-253 (2014-0528) (NCT02267863)
• DS-3032B (2014-0565) (NCT02319369)
• ONC201 (2014-0731) (NCT02392572)
• SL-401(2014-0976) (NCT02268253)
• AMG 330 (2015-0296) (NCT02520427)
• Venetoclax + Cobimetinib or Venetoclax + Idasanutlin (2015-0898) (NCT02670044)
• FT-2102 (2016-0150) (NCT02719574)
• INCB059872 (2016-0556) (NCT02712905)
• AMV564 (2016-0646) (NCT03144245)
• K0706 (2016-0648) (NCT02629692)
• SEL24 (2016-0713) (NCT03008187)
• Palbociclib (2016-0772) (NCT03132454)
• Venetoclax + AZA (2016-0944) (NCT02966782)
• DS-3201b (2016-1130) (NCT03110354)
• MGD006 (2017-0027) (NCT02152956)
• ABBV-744 (2017-0172) (NCT03360006)
• AMG 176 (2017-0776) (NCT02675452)
• IMGN632 (2017-0855) (NCT03386513)
• S64315 (2017-0900) (NCT02979366)
• Thrombosomes (2018-0087) (NCT03394755)
• DS3032b + Quizartinib (2018-0278) (NCT03552029)
• MCLA-117 (2018-0284) (NCT03038230)
• AZD2811 (2018-0319) (NCT03217838)
• DS-3032b + LD Ara-C (2018-0333) (NCT03634228)
• DCLL9718S + AZA (2018-0367) (NCT03298516)
• AMG 397 (2018-0484) (NCT03465540)
• APG-2575 (2018-0527) (NCT03537482)
• CYC140 (2018-0549) (NCT03884829)
• Brequinar (2018-0556) (NCT03760666)
• Venetoclax + Gilteritinib (2018-0675) (NCT03625505)
• AMG427 (2018-0596) (NCT03541369)
• Quizartinib + Venetoclax (2018-0608) (NCT03735875)
• GSK3326595 (2018-0634) (NCT03614728)
• MEDI7247 (2018-1019) (NCT03106428)
• CK 0801 (2018-0010) (NCT03773393)
• ABBV-621 (2018-0676) (NCT03082209)
• CYC065 + Venetoclax (2019-0241) (NCT04017546)
• UCART22 (2017-1003) (NCT04150497)
• PTC299 (2019-0122) (NCT03761069)
• Sapacitabine (2009-1002) (NCT01211457)
• brequinar (2018-0556) (NCT03760666)
• Hu5F9-G4 + AZA (2017-0795) (NCT03248479)
• CPX-351 (2018-0911) (NCT03896269)
• PBCAR0191 (2019-0218) (NCT03666000)
• PLX51107 (2018-0725) (NCT04022785)
• IMG632 + Ven +/- AZA (2019-0656) (NCT04086264)
• Venetoclax + Dinaciclib (2018-0640) (NCT03484520)
• JNJ-64619178 (2019-0340) (NCT03573310)
• APR-246 + Ven +/- AZA (2019-0760) (NCT04214860)
• Atezolizumab + Hu5F9-G4 (2019-0688) (NCT03922477)
• HQP1351 (2019-0705)
• AZA + Ven + Gilteritinib (2019-0366) (NCT04140487)
• PRT543 (2019-0113) (NCT03886831)

Acute Lymphoblastic Leukemia (ALL)

Newly Diagnosed or Previously Treated

• Hyper CVAD + Blinatumomab (2014-0845) (NCT02877303)
• mHCVD + Inotuzumab +/-Blinatumomab (2010-0991) (NCT01371630)
• Venetoclax + Chemo (2016-0694) (NCT03319901)
• Hyper-CVAD + Nelarabine (2006-0328) (NCT00501826)
• Hyper-CVAD + Ponatinib (2011-0030) (NCT01424982)
• Ponatinib vs. Imatinib + Reduced Intensity Chemo (2018-0434) (NCT03589326)
• Blinatumomab + Ponatinib (2016-0792) (NCT03263572)
• Bosutinib + Inotuzumab (2014-0435) (NCT02311998)
• Hyper CVD + Ponatinib (2016-0402) (NCT03147612)
• EPOCH + Ofatumumab (2014-0123) (NCT02199184)

Minimal Residual Disease

• Blinatumomab (2014-0844) (NCT02458014)
• Inotuzumab (2015-0921) (NCT03441061)

Salvage Programs

• Low-Intensity Chemo + Venetoclax (2016-0629) (NCT03808610)
• ADCT-602 (2017-0938) (NCT03698552)
• UCART22 (2017-1003) (NCT04150497)
• Chemo + Blinatumomab (2017-0127) (NCT03518112)
• UCART19 (2016-0725) (NCT02746952)
• iC9/CAR (2016-0641) (NCT03056339)
• Venetoclax + Navitoclax + Chemo (2017-0679) (NCT03181126)
• Ruxolitinib or Dasatinib + HyperCVAD (2014-0521) ( NCT02420717)
• EPOCH + Ofatumumab (2014-0123) (NCT02199184)
• CEC + VCR + Bortezomib (2016-0211) (NCT03136146)
• Venetoclax + Chemo (2016-0694) (NCT03319901)
• Blinatumomab + Ponatinib (2016-0792)  (NCT03263572)
• Bosutinib + Inotuzumab (2014-0435)  (NCT02311998)
• Hyper CVD + Ponatinib (2016-0402) (NCT03147612)
• Ponatinib + Venetoclax (2017-0313) (NCT03576547)
• BL-8040 + Nelarabine (2016-1101) (NCT02763384)
• Hyper-CVAD + Nelarabine (2006-0328) (NCT00501826)
• Palbociclib (2016-0772) (NCT03132454)

Phase I/II Open to ALL

• mHCVD + Inotuzumab +/- Blinatumomab (2010-0991) (NCT01371630)
• DS-3201B (2016-1130) (NCT03110354)
• CYC140 (2018-0549)  (NCT03884829)
• ONC201 (2014-0731) (NCT02392572)

Acute Myelogenous Leukemia (AML)

Newly Diagnosed

• Fludarabine + Ara-C + G-CSF + Gemtuzumab (2007-0147) (NCT00801489)
• ATRA and arsenic +/- Gemtuzumab (2010-0981) (NCT01409161)
• Cladribine + Ida + Ara-C (2012-0648) (NCT02115295)
• FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
• CPX-351 + Venetoclax (2017-1055) (NCT03629171)
• CLIA + Quizartinib (2017-0153) (NCT04047641)
• BP1001 + LD Ara-C (2016-0128) (NCT02781883)
• Dexrazoxane (2017-0937) (NCT03589729)
• Pracinostat + AZA (2017-0173) (NCT03151408)
• Venetoclax + Cladribine + LDAC + LDAC w/ AZA (2018-0020) (NCT03586609) 
• Ida + Ara-C + Dauno (2019-0100) (NCT03850535)
• Cladribine + LD Ara-C alternating DAC (2011-0987) (NCT01515527)
• Nivolumab + AZA (2014-0861) (NCT02397720)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• Dexrazoxane (2017-0937) (NCT03589729)
• MCLA-117 (2018-0284) (NCT03038230)
• AML123 (2017-0559) (NCT03190278)
• DCLL9718S + AZA (2018-0367) (NCT03298516)
• PCM-075 + LDAC (2017-0173) (NCT03151408)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• SL401 + AZA (2017-0354) (NCT03113643)

FLT3 Mutated Only

• CLIA + Quizartinib (2017-0153) (NCT04047641)
• Quinzartinib + DAC (2018-0394) (NCT03661307)

IDH Mutated only

• FT-2102 (2016-0150) (NCT02719574)
• AG120 (2017-0490) (NCT03471260)
• AG221 (2016-0981) (NCT03383575)
• Enasidenib + AZA (2018-0499) (NCT03683433)

Frontline AML Post-Hypomethylating Therapy for MDS

• Nivolumab + AZA (2014-0861) (NCT02397720)
• MCLA-117 (2018-0284) (NCT03038230)
• DCLL9718S + AZA (2018-0367) (NCT03298516)
• BP1001 + LD Ara-C (2016-0128) (NCT02781883)

Secondary Leukemia

• AZA + ABT-199 + Pevonedistat (2018-0724) (NCT03862157)
• Ruxolitinib + DAC (2014-0344) (NCT02257138)

Mixed Phenotype Acute Leukemia

• Clofarabine, Ida, Ara-C, VCR, and Corticosteroids (2013-0073) (NCT02135874)

Salvage

FLT3 Positive at relapse

• CLIA + Quizartinib (2017-0153) (NCT04047641)
• AlloSCT Initial Salvage Therapy (2014-0358) (NCT02441803)
• Quinzartinib + DAC (2018-0394) (NCT03661307)
• DS3032b + Quizartinib (2018-0278) (NCT03552029)
• Venetoclax + Gilteritinib (2018-0675) (NCT03625505)
• CPX-351 + Venetoclax (2017-1055) (NCT03629171)
• Palbociclib (2016-0772) (NCT03132454)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• Cladribine + Ida + Ara-C + Sorafenib (2012-0648) (NCT02115295)
• MCLA-117 (2018-0284) (NCT03038230)
• AMG 330 (2015-0296) (NCT02520427)
• FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
• AMG673 (2017-0365) (NCT03224819)
• DCLL9718S + AZA (2018-0367) (NCT03298516)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• Daratumumab (2016-0889) (NCT03067571)
• DS-3032b + LD Ara-C (2018-0333) (NCT03634228)

RAS Mutated

• AlloSCT Initial Salvage Therapy (2014-0358) (NCT02441803)
• FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• MCLA-117 (2018-0284) (NCT03038230)
• AMG 330 (2015-0296) (NCT02520427)
• AMG673 (2017-0365) (NCT03224819)
• DCLL9718S + AZA (2018-0367) (NCT03298516)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• Daratumumab (2016-0889) (NCT03067571)
• CPX-351 + Venetoclax (2017-1055) (NCT03629171)
• DS-3032b + LD Ara-C (2018-0333) (NCT03634228)

AML with MLL gene at 11q23 Translocations

• DS-3032b + LD Ara-C (2018-0333) (NCT03634228)

IDH Mutated

• FT-2102 (2016-0150) (NCT02719574)
• AG120 (2017-0490) (NCT03471260)
• Enasidenib + AZA (2018-0499) (NCT03683433)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• AMG 330 (2015-0296) (NCT02520427)
• XmAb 14045 (2016-0165) (NCT02730312)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• Daratumumab (2016-0889) (NCT03067571)
• AG221 (2016-0981) (NCT03383575)
• DS-3032b + LD Ara-C (2018-0333) (NCT03634228)

All others (Regardless of mutation status)

• CPX-351 + Venetoclax (2017-1055) (NCT03629171)
• AlloSCT Initial Salvage Therapy (2014-0358) (NCT02441803)
• FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
• Pilot Study CPX-351 w/ Gemtuzumab (2018-0235) (NCT03672539)
• Cladribine + Ida + Ara-C + Sorafenib (2012-0648) (NCT02115295)
• Idasanutlin + Ara-C vs Ara-C + Placebo (2017-1051) (NCT02545283)
• Nivolumab + 5-AZA (2014-0861) (NCT02397720)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• MCLA-117 (2018-0284) (NCT03038230)
• DS-3032B (2014-0565) (NCT02319369)
• AMG 330 (2015-0296) (NCT02520427)
• AML123 (2017-0559) (NCT03190278)
• DCLL9718S + AZA (2018-0367) (NCT03298516)
• OX40 (2017-0337) (NCT03390296)
• GO + Glasdegib (2017-0337) (NCT03390296)
• GO + AZA (2017-0337) (NCT03390296)
• AZA + Ven + Avelumab (2017-0337) (NCT03390296)
• AMG673 (2017-0365) (NCT03224819)
• Daratumumab (2016-0889) (NCT03067571)
• SL401 + AZA (2017-0354) (NCT03113643)
• Chemo +/- Uproleselan (2018-0467) (NCT03616470)
• MGD006 (2017-0027) (NCT02152956)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• DS-3032b + LD Ara-C (2018-0333) (NCT03634228)
• PTC299 (2019-0122) (NCT03761069)
• DFP-10917 vs Non-Intensive Reinduction (2019-0357) (NCT03926624)

Maintenance (Patients in CR)

• AZA + Venetoclax (2019-0226) (NCT04062266)
• Lenalidomide (2014-0116) (NCT02126553)
• Nivolumab (2015-0213) (NCT02532231)

Supportive Care for AML

• Isavuconazole (2016-0373) (NCT03019939)
• Thrombosomes (2018-0087) (NCT03394755)
• Detoxifying the Bone Marrow Microenvironment (2017-0752) (NCT03630991)

BPDCN Treatment Priorities

• Venetoclax (2018-0841) (NCT03485547)

Myelodysplastic Syndrome (MDS) (Includes CMML)

Specific Situations

Hypoplastic MDS and aplastic anemia

• Horse ATG (2012-0334) (NCT01624805)
• BL-8040 (2015-0408) (NCT02462252)

Splicing Mutations

• GSK3326595 (2018-0634) (NCT03614728)

MDS/MPN

• Ruxolitinib + AZA (2012-0737) (NCT01787487)
• SL-401 (CMML) (2014-0976) (NCT02268253)

FLT3 Positive

• Quinzartinib + DAC (2018-0394) (NCT03661307)

IDH Mutations

• FT-2102 (2016-0150) (NCT02719574)
• AG221 (2016-0981) (NCT03383575)

P53 Mutations

• APR-246 + AZA vs AZA Alone (2018-0912) (NCT03745716)

Low Risk/IPSS Int-1

• ASTX727-03  (2018-0919) (NCT03502668)
• DAC vs AZA (2014-0112) (NCT02269280)
• Roxadustat (FG-4592)/Placebo (2017-0042) (NCT03263091)
• ACE-536 vs Epoetin (2018-0179) (NCT03682536)
• Hu5F9-G4 + AZA (2017-0795) (NCT03248479)

IPSS int-2 or high

• Venetoclax + AZA vs AZA Alone (2016-0757) (NCT02942290)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• Nivolumab + Ipilimumab + Aza (2014-0930) (NCT02530463)
• Pembrolizumab + AZA (2016-0343) (NCT03094637)
• CB-839 + AZA (2016-0636) (NCT03047993)
• Cladribine + LD Ara-C alt DAC (2011-0987) (NCT01515527)
• Cladribine + Ida + Ara-C + Sorafenib (2012-0648) (NCT02115295)
• FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• Hu5F9-G4 + AZA (2017-0795) (NCT03248479)

Post Hypomethylating Agents

• Nivolumab + Ipilimumab + Aza (2014-0930) (NCT02530463)
• Pembrolizumab + AZA (2016-0343) (NCT03094637)
• SGI-110 (2016-0587) (NCT02907359)
• SL-401(2014-0976) (NCT02268253)
• Roxadustat (FG-4592)/Placebo (2017-0042) (NCT03263091)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• CPX-351 (2018-0911) (NCT03896269)
• AMV564-201 (2018-0009) (NCT03516591)
• Venetoclax + AZA (2016-0944) (NCT02966782)
• Nivolumab + Ipilimumab + Aza (2014-0930) (NCT02530463)
• SGI-110 (2016-0587) (NCT02907359)
• Rigosertib (2015-0360) (NCT02562443) 
• Pembrolizumab + AZA (2016-0343) (NCT03094637)
• Rigosertib (2015-0360) (NCT02562443)
• CB-839 + AZA (2016-0636) (NCT03047993)
• FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• Pilot Study CPX-351 w/ Gemtuzumab (2018-0235) (NCT03672539)

Chronic Lymphocytic Leukemia (CLL)

CLL Immunotherapy

Untreated - early stage

• Ibrutinib (2017-0039) (NCT03207555)
• INVAC-1 (2017-0836) (NCT03265717)

Untreated - all stages

• FCIG (2015-0281) (NCT02629809)
• Atezolizumab (2015-1097) (NCT02846623)

Consolidation and Minimal Residual Disease (MRD)

• ABT-199 + Ibrutinib (2016-0785) (NCT03128879)
• INVAC-1 (2017-0836) (NCT03265717)

Prior Therapy

• LOXO-305 (2018-0850) (NCT03740529)
• SNS-062 – BTK-Inhibitor (2017-0158) (NCT03037645)
• CYC065+VEN (2018-0316) (NCT03739554)
• KTE-19 (2018-0767) (NCT03624036)
• APG-2575 (Bcl-2-i) (2018-0527) (NCT03537482)
• UC-961 + Ibrutinib (2017-0889) (NCT03088878)
• XmAb®13676 (2016-0991) (NCT02924402)
• iC9/CAR (2016-0641) (NCT03056339)
• JCAR017 (2017-0751) (NCT03331198)
• AZD5991 (2017-0702) (NCT03218683)

Richter’s Transformation

• Blinatumomab (2016-0765) (NCT03121534)
• XmAb®13676 (2016-0991) (NCT02924402)
• iC9/CAR (2016-0641) (NCT03056339)
• Atezolizumab (2015-1097) (NCT02846623)
• EPOCH-R + VEN (2016-0900) (NCT03054896)

Other Studies

• PCI-32765 in Hairy Cell Leukemia (2013-0299) (NCT01841723)
• 2CDA + Rituximab in Hairy Cell Leukemia (2004-0223) (NCT00412594)

Chronic Myelogenous Leukemia (CML)

Chronic phase

• Dasatinib (2015-1040) (NCT02689440) 
• K0706 (2016-0648) (NCT02629692)

Accelerated Phase

• BP1001 (2016-0644) (NCT02923986)
• K0706 (2016-0648) (NCT02629692)

Blastic Phase

• BP1001 (2016-0644) (NCT02923986)
• Dexrazoxane (2017-0937) (NCT03589729)
• Bosutinib + Inotuzumab (2014-0435) (NCT02311998)
• K0706 (2016-0648) (NCT02629692)
• BP1001 (2016-0644) (NCT02923986)
• DS-3032B (2014-0565) (NCT02319369)

Imatinib failures with T315l mutations (any stage)

• K0706 (2016-0648) (NCT02629692)
• Oral ABL001 (2014-1019) (NCT02081378)

Minimal Residual Disease

• Ruxolitinib (2012-0697) (NCT01751425)

Myeloproliferative Neoplasms (MPN)

• Ruxolitinib + Thalidomide (2017-0512) (NCT03069326)
• CPI-0610 (2018-0202) (NCT02158858)
• PU-H71 (2019-0019) (NCT03935555)
• KRT-232 (2018-0906) (NCT03662126)
• Fedratinib (2018-1167) (NCT03755518)
• Navitoclax (2017-0495) (NCT03222609)
• Pacritinib (2017-0320) (NCT03165734)
• PRT543 (2019-0113) (NCT03886831)
• INCB050465 + Ruxolitinib (2016-0233) (NCT02718300)
• SL-401 (2014-0976) (NCT02268253)
• Ruxolitinib + AZA (2012-0737) (NCT01787487)
• Luspatercept (ACE-536) (2017-0504) (NCT03194542)
• Sotatercept (ACE-011) (2012-0534) (NCT01712308)
• PTG-300 (2019-0016) (NCT04057040)
• BLU-285 (2018-0943) (NCT03580655)
• INCB054828 (2016-0635) (NCT03011372)
• Momelotinib/Placebo vs Danazol/Placebo (2019-0998) (NCT04173494)

Hemophagocytic Lymphohistiocytosis

• Alemtuzumab + Etoposide & Dexamethasone (2014-0989)